Literature DB >> 15808135

Community-acquired pneumonia as the initial manifestation of serious underlying diseases.

Miquel Falguera1, Mariela Martín, Agustín Ruiz-González, Ricard Pifarré, Mercè García.   

Abstract

PURPOSE: Community-acquired pneumonia is common among patients with coexisting illnesses and it can be the initial manifestation of these comorbid diseases. The objectives of our study were to evaluate the frequency of this association and to analyze whether certain characteristics could predict the presence of unknown comorbid conditions. SUBJECTS AND METHODS: Over a 5-year period, we prospectively studied 660 consecutive patients with community-acquired pneumonia seen at our institution. In a subgroup of these patients, diagnosis of previously unknown comorbid conditions was established during follow-up. Characteristics of these patients were compared with data from the remaining sample of patients.
RESULTS: Prior underlying diseases were present in 298 (45%) patients. One or more new comorbid conditions were found in 41 (6%), of which diabetes (14 cases), malignancies (12 cases), chronic obstructive pulmonary disease (8 cases), and human immunodeficiency virus (HIV) infection (5 cases) were the most common. In the comparative study, a bacterial etiology, positive blood cultures, and hospitalization were more frequently found (P < 0.05) in patients with new comorbid conditions than atypical microorganisms or viruses, negative blood cultures, or outpatient care.
CONCLUSION: In the initial diagnostic workup of patients with community-acquired pneumonia, the possibility of unknown comorbid conditions should be carefully evaluated.

Entities:  

Mesh:

Year:  2005        PMID: 15808135     DOI: 10.1016/j.amjmed.2005.01.011

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

Review 1.  [Assessment, triage, and follow-up of a patient with: acute CAP COPD].

Authors:  K Faure
Journal:  Med Mal Infect       Date:  2006-11-07       Impact factor: 2.152

2.  Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin.

Authors:  Joo H Lee; Myung G Lee
Journal:  Pharm Res       Date:  2008-05-14       Impact factor: 4.200

3.  Bacteraemic pneumococcal pneumonia in COPD patients: better outcomes than expected.

Authors:  E Calbo; E Valdés; A Ochoa de Echagüen; A Fleites; L Molinos; M Xercavins; N Freixas; M Rodríguez-Carballeira; J Garau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-10       Impact factor: 3.267

4.  The mortality risk factor of community acquired pneumonia patients with chronic obstructive pulmonary disease: a retrospective cohort study.

Authors:  Ruo-Xuan Dai; Qing-Hua Kong; Bei Mao; Wen Xu; Ru-Jia Tao; Xiao-Ru Wang; Qing-Yao Kong; Jin-Fu Xu
Journal:  BMC Pulm Med       Date:  2018-01-22       Impact factor: 3.317

5.  Implications of Emphysema and Lung Function for the Development of Pneumonia in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Yoonki Hong; Jae Seung Lee; Kwang Ha Yoo; Ji-Hyun Lee; Woo Jin Kim; Seong Yong Lim; Chin Kook Rhee; Sang-Do Lee; Yeon-Mok Oh
Journal:  Tuberc Respir Dis (Seoul)       Date:  2016-03-31

Review 6.  Resolving Viral-Induced Secondary Bacterial Infection in COPD: A Concise Review.

Authors:  Hao Wang; Desiree Anthony; Stavros Selemidis; Ross Vlahos; Steven Bozinovski
Journal:  Front Immunol       Date:  2018-10-16       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.